• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022

    2/10/22 5:00:00 PM ET
    $AZN
    $NDAQ
    $XLNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AZN alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

    For more information about the company, go to https://www.astrazeneca.com.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Media Contact

    Emily Pan

    [email protected]

    +1 (646) 637-3964

    Issuer & Investor Contact

    Index Client Services

    [email protected]

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $NDAQ
    $XLNX

    CompanyDatePrice TargetRatingAnalyst
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    Nasdaq Inc.
    $NDAQ
    1/8/2025$80.00 → $98.00Hold → Buy
    Deutsche Bank
    Nasdaq Inc.
    $NDAQ
    11/25/2024Outperform
    William Blair
    More analyst ratings

    $AZN
    $NDAQ
    $XLNX
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/18/25 11:07:43 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/15/25 10:40:25 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/12/25 10:45:07 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Begley Charlene T sold $289,800 worth of shares (3,000 units at $96.60), decreasing direct ownership by 6% to 46,001 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    8/6/25 4:00:45 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    EVP, CSO Skule Jeremy sold $201,006 worth of shares (2,105 units at $95.49), decreasing direct ownership by 2% to 92,551 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    8/5/25 4:03:14 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SVP, Controller & PAO Daly Michelle Lynn sold $812,174 worth of shares (8,691 units at $93.45), decreasing direct ownership by 49% to 8,879 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    7/29/25 4:17:46 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Torgeby Johan bought $705,880 worth of shares (14,000 units at $50.42), increasing direct ownership by 165% to 22,466 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/25/23 4:02:10 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery

    AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815310613/en/ Initially approved by the Food and Drug Admin

    8/15/25 8:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact

    The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J., Aug. 13, 2025 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced the recipients of its 2025 Advancement, Commitment, and Engagement (ACE) Awards, honoring high-impact programs that are redefining workforce development across the healthcare industry. The ACE Awards recognize standout programs with bold strategies that prioritize people, scale globally, deliver measurable business and social outcomes, and honor the future of leadership and innovation in healthcare. This year's honorees include:

    8/13/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 31, 2025

    NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of July 31, 2025, short interest in 3,285 Nasdaq Global MarketSM securities totaled 13,683,072,188 shares compared with 13,792,841,090 shares in 3,260 Global Market issues reported for the prior settlement date of July 15, 2025. The mid-July short interest represents 2.15 days compared with 2.37 days for the prior reporting period. Short interest in 1,658 securities on The Nasdaq Capital MarketSM totaled 2,910,549,464 shares at the end of the settlement date of July 31, 2025, compared with 2,853,251,720 shares in 1,647 securities for the previous reporting period. This represents a 1.00 day average daily volume;

    8/11/25 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NASDAQ upgraded by UBS with a new price target

    UBS upgraded NASDAQ from Neutral to Buy and set a new price target of $115.00

    7/25/25 8:52:40 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    NASDAQ upgraded by Redburn Atlantic with a new price target

    Redburn Atlantic upgraded NASDAQ from Neutral to Buy and set a new price target of $91.00

    4/17/25 8:27:31 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Leadership Updates

    Live Leadership Updates

    View All

    Thomson Reuters Corp to Join the Nasdaq-100 Index® Beginning July 28, 2025

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Thomson Reuters Corp (NASDAQ:TRI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (NASDAQ:ANSS) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. ANSYS, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:ND

    7/18/25 8:00:00 PM ET
    $ANSS
    $NDAQ
    $TRI
    Computer Software: Prepackaged Software
    Technology
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Welcomes 142 IPOs in the First Half of 2025

    Highest volume of listings and capital raise in the first half of the year since 2021 Maintained leadership in switches - crossed $3 trillion in market value transferred since 2005 Driving smart policy reforms to improve regulatory processes for public companies NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) announced today that in the first half of 2025, it welcomed 142 listings (IPOs), raising a total of $19.2 billion. A total of 83 operating companies and 59 SPACs listed on Nasdaq during the first six months of 2025, representing an 86% win-rate of Nasdaq-eligible listings in the U.S. market, and extending Nasdaq's leadership to 46 consecutive quarters. In add

    7/1/25 8:05:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Announces Results from 2025 Annual Meeting of Shareholders

    All 12 Nominated Directors Elected Nasdaq Board Re-elects Adena T. Friedman as Chair of the Board NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (NASDAQ:NDAQ) shareholders elected all nominated directors at the company's Annual Meeting of Shareholders on Wednesday, June 11, 2025. All directors will serve one-year terms. The elected board members are: Melissa M. Arnoldi, EVP and General Manager for Business Solutions, AT&T Inc.Charlene T. Begley, Retired SVP and CIO, General Electric CompanyAdena T. Friedman, Chair and CEO, NasdaqEssa Kazim, Governor, Dubai International Financial CentreThomas A. Kloet, Retired CEO and Executive Director, TMX Group LimitedKathryn A. Koch, Presi

    6/16/25 4:30:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Financials

    Live finance-specific insights

    View All

    AstraZeneca results: H1 and Q2 2025

    Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

    7/29/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Announces Quarterly Dividend of $0.27 Per Share

    NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock. The dividend is payable on September 26, 2025 to shareholders of record at the close of business on September 12, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets an

    7/24/25 7:01:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Reports Second Quarter 2025 Results; Double-Digit Net Revenue Growth Reflects Strong Momentum Across All Divisions

    NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (NASDAQ:NDAQ) today reported financial results for the second quarter of 2025. Second quarter 2025 net revenue1 was $1.3 billion, an increase of 13% over the second quarter of 2024, or up 12% on an organic2 basis. This included Solutions3 revenue growing 10%.Annualized Recurring Revenue (ARR)4 of $2.9 billion increased 10% over the second quarter of 2024, or up 9% on an organic basis. Annualized SaaS revenue increased 13%, or 12% on an organic basis, and represented 37% of ARR.Financial Technology revenue of $464 million increased 10% over the second quarter of 2024.Index revenue of $196 million grew 17%, with $88 billion of n

    7/24/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance